Kellie J. Nazemi, M.D.

  • Associate Professor of Pediatrics, Division of Hematology and Oncology, School of Medicine
  • Medical Director, Pediatric Brain Tumor Program


Dr. Nazemi is an Associate Professor in the Division of Pediatric Hematology/Oncology and provides specialized care for children and teens with brain tumors and spinal cord tumors. She works closely with experts in neurosurgery, radiation oncology, neuropathology, and neuroradiology to determine the best treatment approach for each patient. She has built a nationally-respected multi-disciplinary program to support this patient population by partnering with specialized nurses, a social worker and school teacher/liaison, clinical research associates, laboratory scientists, and other important subspecialists in neurology, ophthalmology, endocrinology, audiology, and genetics. She has also developed a rich collaborative network with colleagues around the country to maximize patient access to clinical trials here at OHSU Doernbecher Children’s Hospital.


  • B.S., 1995, University of Washington
  • M.D., 2000, Texas Tech University Health Sciences Center School of Medicine
  • Residency:

    • Children's Hospital of the King's Daughters, Eastern Virginia Medical School (2000 - 2003)
  • Fellowship:

    • Children's Hospital Boston / Dana-Farber Cancer Institute, Harvard Medical School (2003 - 2006)
  • Certifications:

    • American Board of Pediatrics, 2003
    • American Board of Pediatrics, Sub-board of Pediatric Hematology-Oncology, 2006 (re-certified 2016)

Memberships and associations

  • Pacific Pediatric Neuro-Oncology Consortium (PNOC)
  • Society for Neuro-Oncology (SNO)
  • Children’s Oncology Group (COG)

Areas of interest

  • Brain and spinal cord tumors
  • Patient access to clinical trials and novel treatments


Selected publications

  • National collaborative work published: Phase I study of vemurafenib in children with recurrent or progressive BRAGV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). 2020
  • Measure Twice: Promise of Liquid Biopsy in Pediatric High Grade Gliomas. 2020
  • A pilot precision medicine trial for children with diffuse intrinsic pontine glioma: PNOC-003: a report from the Pacific Pediatric Neuro-Oncology Consortium. 2019
  • Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. 2018
  • High Incidence of Veno-Occlusive Disease With Myeloablative Chemotherapy Following Craniospinal Irradiation in Children with Newly Diagnosed High-Risk CNS Embryonal Tumors: A Report from the Chidren’s Oncology Group (CCG-99702). 2016


  • {{[0].value }}
    1. {{ }} {{ }}